Program
Celecoxib
Also written as “celecoxib”, “Celecoxib 200mg” and “Celecoxib + Acetaminophen”.
Its studies are mostly in Osteoarthritis · Osteoarthritis, Knee · Low Back Pain · Migraine Disorders · Pain, Postoperative, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 320 open or running | phase 4since Aug 26, 2005 | Aug 26, 2005 | none ahead |
| Pfizer | 100 open or running | phase 4since Sep 9, 2005 | May 8, 2002 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 2since Jun 8, 2015 | Jun 8, 2015 | none ahead |
| NeuroSense Therapeutics | 40 open or running | phase 2since Nov 13, 2019 | Aug 29, 2019 | none ahead |
| Leidos Life Sciences | 30 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| BioDelivery Sciences International | 20 open or running | phase 3since Dec 27, 2016 | Dec 27, 2016 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 20 open or running | phase 3since Jun 26, 2024 | Jun 26, 2024 | none ahead |
| Aralez Pharmaceuticals | 10 open or running | phase 1since Aug 5, 2008 | Aug 5, 2008 | none ahead |
| arthritis-innovation-corporation | 10 open or running | phase 2since May 8, 2018 | May 8, 2018 | none ahead |
| Astellas Pharma | 10 open or running | phase 3since May 5, 2010 | May 5, 2010 | none ahead |
| Bausch Health Companies | 10 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Feb 3, 2017 | Feb 3, 2017 | none ahead |
| Dong-A ST | 10 open or running | phase 4since May 19, 2016 | May 19, 2016 | none ahead |
| kitov-pharmaceuticals-ltd | 10 open or running | phase 3since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Mundipharma | 10 open or running | phase 3since Feb 20, 2017 | Feb 20, 2017 | none ahead |
| x-pert-med-gmbh | 10 open or running | phase 1since Nov 9, 2009 | Nov 9, 2009 | none ahead |
Also a collaborator on its studies: AstraZeneca.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Aug 29, 2005.
- Dec 27, 2016BioDelivery Sciences International's first studies: 2 phase 3 studies in Migraine DisordersNew to BioDelivery Sciences InternationalBioDelivery Sciences International · NCT03009019, NCT03006276
- Feb 3, 2017Chong Kun Dang Pharmaceutical's first study: phase 4 study in Osteoarthritis HandNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03067194 · 117 enrolled · Korea, Republic of
- Feb 7, 2017Phase 1 study in HealthyDr. Reddy's Laboratories · NCT03051685 · 16 enrolled · United States
- Feb 20, 2017Mundipharma's first study: phase 3 study in Acute PainNew to MundipharmaMundipharma · NCT03062644 · 1,138 enrolled · Belarus, Bulgaria, Canada and more
- Aug 17, 2017Phase 1 study in Migraine DisordersDr. Reddy's Laboratories · NCT03282838 · 24 enrolled · United States
- May 8, 2018arthritis-innovation-corporation's first study: phase 2 study in Pain, PostoperativeNew to arthritis-innovation-corporationarthritis-innovation-corporation · NCT03541655 · 20 enrolled · United States
- May 21, 2018Phase 2 study in Acute PainDr. Reddy's Laboratories · NCT03554772 · 120 enrolled · United States
- Aug 29, 2019NeuroSense Therapeutics's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to NeuroSense TherapeuticsNeuroSense Therapeutics · NCT04090684 · 10 enrolled · United States
- Nov 13, 2019Phase 2 study in Amyotrophic Lateral SclerosisNeuroSense Therapeutics · NCT04165850 · 16 enrolled · Israel
- Oct 7, 2021Leidos Life Sciences's first studies: 3 phase 2 studies in COVID-19New to Leidos Life SciencesLeidos Life Sciences · NCT05085574, NCT05077969, NCT05077332
- Jan 19, 2022Phase 1 study in PharmacokineticsNeuroSense Therapeutics · NCT05232461 · 12 enrolled · United States
- Jun 22, 2022Phase 1 study in PharmacokineticsNeuroSense Therapeutics · NCT05436678 · 19 enrolled · United States
- Jun 26, 2024Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in Low Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT06516094 · 192 enrolled · Mexico
- Mar 3, 2025Phase 3 study in ArthralgiaLaboratorios Silanes S.A. de C.V. · NCT06863636 · 231 enrolled · Mexico
TargetBeta
“Cyclooxygenase-2 inhibitor”ChEMBL 37, by rule
Other programs on PTGS2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| Meloxicamrule | Boehringer Ingelheim | phase 4 | 67 |
| Etoricoxibrule | Organon | phase 4 | 35 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06863636Arthralgia · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Oct 30, 2025 | 231 |
| NCT06516094Low Back Pain · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Jan 1, 2025 | 192 |
| NCT05436678Pharmacokinetics · United States | 1 | Completed | NeuroSense Therapeutics | Aug 19, 2022 | 19 |
| NCT05232461Pharmacokinetics · United States | 1 | Completed | NeuroSense Therapeutics | Apr 21, 2022 | 12 |
| NCT05085574COVID-19 | 2 | Withdrawn | Leidos Life Sciences | Feb 7, 2023 | 0 |
| NCT05077969COVID-19 · United States | 2 | Terminated | Leidos Life Sciences | Jun 28, 2022 | 4 |
| NCT05077332COVID-19 · United States | 2 | Completed | Leidos Life Sciences | Nov 10, 2025 | 4 |
| NCT04165850Amyotrophic Lateral Sclerosis · Israel | 2 | Completed | NeuroSense Therapeutics | Jan 19, 2021 | 16 |
| NCT04090684Amyotrophic Lateral Sclerosis · United States | 1 | Completed | NeuroSense Therapeutics | Sep 27, 2021 | 10 |
| NCT03554772Acute Pain · United States | 2 | Completed | Dr. Reddy's Laboratories | Aug 20, 2018 | 120 |
| NCT03541655Pain, Postoperative · United States | 2 | Completed | arthritis-innovation-corporation | Jun 20, 2019 | 20 |
| NCT03282838Migraine Disorders · United States | 1 | Completed | Dr. Reddy's Laboratories | Aug 22, 2017 | 24 |
| NCT03062644Acute Pain · Belarus, Bulgaria, Canada and more | 3 | Completed | Mundipharma | Jun 29, 2018 | 1,138 |
| NCT03051685Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Aug 14, 2015 | 16 |
| NCT03067194Osteoarthritis Hand · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 10, 2017 | 117 |
| NCT03009019Migraine Disorders · United States | 3 | Completed | BioDelivery Sciences International | Nov 2017 | 631 |
| NCT03006276Migraine Disorders · United States | 3 | Completed | BioDelivery Sciences International | Nov 2017 | 622 |
| NCT02780323Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Dong-A ST | Dec 26, 2017 | 119 |
| NCT02472418Migraine Disorders · United States | 2 | Completed | Dr. Reddy's Laboratories | Dec 1, 2015 | 63 |
| NCT02172040Hypertension · United Kingdom | 3 | Completed | kitov-pharmaceuticals-ltd | Nov 19, 2015 | 152 |
| NCT01838044Chronic Low Back Pain With a Neuropathic Component · Brazil, Chile, Colombia and more | 4 | Terminated | Viatris | May 2015 | 180 |
| NCT01118572Pain, Postoperative · Japan | 3 | Completed | Astellas Pharma | Nov 2010 | 616 |
| NCT01062113Pain · Japan | 2 | Completed | Viatris | Aug 2010 | 255 |
| NCT01020279Musculoskeletal Pain · Germany | 1 | Completed | x-pert-med-gmbh | 82 | |
| NCT00994461Healthy Volunteers · Japan | 4 | Completed | Viatris | Apr 2010 | 190 |
| NCT00976716Pain · Japan | 3 | Completed | Viatris | Nov 2009 | 80 |
| NCT00894790Pain · Mexico | 4 | Terminated | Viatris | Jan 2010 | 8 |
| NCT00807846Arthritis, Juvenile · United States, Chile, Costa Rica and more | 4 | Completed | Viatris | Dec 2012 | 201 |
| NCT00762463Spondylitis, Ankylosing · China | 3 | Completed | Viatris | Jun 2010 | 240 |
| NCT00729495Healthy Volunteer · United States | 1 | Completed | Aralez Pharmaceuticals | Aug 2008 | 80 |
| NCT00663767Toothache · United States | 2 | Completed | Pfizer | Jun 20, 2008 | 250 |
| NCT00652925Arthritis, Juvenile · United States, Belgium, Brazil and more | 3 | Completed | Pfizer | Apr 2004 | 225 |
| NCT00648141Spondylitis, Ankylosing · Germany | 3 | Completed | Pfizer | 458 | |
| NCT00643799Osteoarthritis, Knee · United States | 4 | Completed | Viatris | Jan 2005 | 586 |
| NCT00640809Inflammatory Bowel Diseases · United States | 4 | Completed | Viatris | 408 | |
| NCT00640627Osteoarthritis, Knee · United States | 4 | Completed | Viatris | 380 | |
| NCT00640432Low Back Pain · Brazil | 4 | Completed | Viatris | 244 | |
| NCT00639483Schizophrenia · Argentina, Brazil, Germany and more | 2 | Completed | Pfizer | 270 | |
| NCT00638807Osteoarthritis, Knee · United States | 4 | Completed | Viatris | 388 | |
| NCT00633438Arthroscopy · United States | 4 | Completed | Viatris | 204 | |
| NCT00633386Arthroscopy · United States | 4 | Completed | Viatris | 200 | |
| NCT00630929Osteoarthritis, Knee · Germany, Spain, United Kingdom | 4 | Completed | Viatris | 388 | |
| NCT00620867Osteoarthritis, Knee · United States | 4 | Completed | Viatris | Mar 2003 | 393 |
| NCT00585312Adenomatous Polyposis Coli · United States, Belgium, Czechia and more | 3 | Terminated | Viatris | Oct 2013 | 106 |
| NCT00662558Low Back Pain · United States | 3 | Completed | Viatris | Sep 2008 | 802 |
| NCT00549549Arthritis, Gouty · United States, Canada, Colombia and more | 3 | Completed | Viatris | Dec 2009 | 402 |
| NCT00484718Osteoarthritis · United States | 4 | Terminated | Pfizer | Jun 10, 2009 | 6 |
| NCT00446797Ankle Injuries · Brazil, Costa Rica, Ecuador and more | 4 | Completed | Viatris | Apr 2008 | 278 |
| NCT00402987Pharyngitis · United States | 3 | Completed | Viatris | Nov 15, 2007 | 269 |
| NCT00373685Osteoarthritis · United States, Puerto Rico | 4 | Completed | Viatris | Nov 2010 | 8,067 |
| NCT00359151Osteoarthritis · United States | 4 | Terminated | Viatris | 22 | |
| NCT00348452Chronic Pain | 3 | Completed | Bausch Health Companies | 1,000 | |
| NCT00346216Arthritis, Rheumatoid · United States, Australia, Brazil and more | 4 | Completed | Viatris | Apr 12, 2016 | 24,081 |
| NCT00296127Healthy Volunteers · United States | 1 | Completed | Viatris | 24 | |
| NCT00290901Back Pain · United States, Puerto Rico | 4 | Completed | Viatris | Dec 2006 | 754 |
| NCT00174317Osteoarthritis, Hip · United Kingdom | 4 | Completed | Pfizer | 250 | |
| NCT00163241Osteoarthritis · Canada, France | 3 | Terminated | Viatris | 666 | |
| NCT00150280Pain, Postoperative · China | 3 | Completed | Viatris | 132 | |
| NCT00141154Low Back Pain · Japan | 3 | Completed | Viatris | 1,234 | |
| NCT00141102Osteoarthritis · Belgium, Brazil, Canada and more | 4 | Completed | Viatris | May 2009 | 4,484 |
How it is read
Names in the registry
- “Celecoxib”, 49 entries
- “celecoxib”, 7 entries
- “Celecoxib 200mg”, 3 entries
- “Celecoxib + Acetaminophen”, 2 entries
- “Comparator: celecoxib”, 2 entries
Codes read as this program: DFN15.
Conditions, from the studies’ own filings
- Osteoarthritis, 8 studies
- Osteoarthritis, Knee, 8 studies
- Low Back Pain, 5 studies
- Migraine Disorders, 4 studies
- Pain, Postoperative, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.